{"nctId":"NCT00647270","briefTitle":"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing","startDateStruct":{"date":"2007-12"},"conditions":["Rheumatoid Arthritis"],"count":420,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: adalimumab"]},{"label":"80 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"Placebo","otherNames":[]},{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject \\> 18 years of age\n* Subject has a diagnosis of RA as defined by the 1987-revised ACR-classification criteria and has a disease duration for a minimum of three months\n* Subject must meet the following two criteria: a) At least 6 swollen joints out of 66 assessed, or b) At least 6 tender joints out of 68 assessed\n* If a subject is on MTX, the doses must be stable for at least 4 weeks prior to Screening blood draw and follow standard recommendations for MTX treatment\n* Subject is judged to be in generally good health as determined by the principal investigator\n\nExclusion Criteria:\n\n* Subject has previous exposure to any systemic anti-TNF therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab\n* Subject has a history of acute inflammatory joint disease of different origin other than RA\n* Subject has been treated with any investigational biologic agents\n* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study\n* Female subject who is pregnant or breast-feeding or considering becoming pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)","description":"Comparison of adalimumab 80 mg monthly dose versus placebo and adalimumab 40 mg eow in the number of responders with ACR criteria improvement consisting of 20%, (ACR20) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20% improvement in 3 of the following 5 criteria: \\[1\\] physician's global assessment of disease activity (PGA), \\[2\\] subject's assessment of disease activity, \\[3\\] subject's assessment of pain, \\[4\\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \\[5\\] C-reactive protein (CRP) at each visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Within Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)","description":"The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.488"},{"groupId":"OG001","value":"-0.41","spread":"0.508"},{"groupId":"OG002","value":"-0.39","spread":"0.536"}]}]}]},{"type":"SECONDARY","title":"Within Group Mean Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])","description":"The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.12","spread":"0.484"},{"groupId":"OG001","value":"-0.40","spread":"0.507"},{"groupId":"OG002","value":"-0.37","spread":"0.537"}]}]}]},{"type":"SECONDARY","title":"Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Observed)","description":"The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"-0.26","spread":"0.081"},{"groupId":"OG002","value":"-0.24","spread":"0.079"}]}]}]},{"type":"SECONDARY","title":"Between Group Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 (Last Observation Carried Forward [LOCF])","description":"The HAQ-DI is a self-reported subject measure of physical function calculated as the mean of 8 category scores: Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each category score is calculated as the maximum of the scores for the questions within the category. The HAQ-DI is expressed on a scale of 0 (without any difficulty) to 3 (unable to do) representing an average score across the category. Scores for at least 6 categories are needed to compute the HAQ score. Changes to lower scores indicate improvement in physical function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"-0.24","spread":"0.077"},{"groupId":"OG002","value":"-0.21","spread":"0.075"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":57},"commonTop":["upper respiratory tract infection","nasopharyngitis","nausea","headache","dizziness"]}}}